EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudie

Predictive Value of Platelet FcγRIIa in Patients Treated With PCI Compared With Medical Therapy Alone After Myocardial Infarction

David J Schneider iD, Sean R McMahon, Dominick J Angiolillo iD, Alexander C Fanaroff iD, Homam Ibrahim, Patrick K Hohl iD, Brett L Wanamaker, Mark B Effron iD, Peter M DiBattiste, Investigators

Circulation: Cardiovascular Interventions · 2025

DOI: 10.1161/circinterventions.124.014939 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Circulation: Cardiovascular Interventions, 2025. Verfasst von David J Schneider und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Cardiovascular Research Institute, The University of Vermont, Burlington (D.J.S.). Hauptthemen laut MEDLINE: Blood Platelets, Non-ST Elevated Myocardial Infarction, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In patients with myocardial infarction (MI), quantifying platelet FcɣRIIa (pFCG) stratifies the risk of subsequent MI, stroke, and death. This report is a subgroup analysis of outcomes in patients treated with percutaneous coronary intervention (PCI) or medical management alone in an 800-patient, 25-center trial. METHODS: Patients were enrolled in a prospective, noninterventional trial during hospitalization for type 1 MI (ST-segment–elevation and non–ST-segment–elevation). Inclusion criteria included at least 2 of the following: aged ≥65 years, multivessel coronary artery disease, prior MI, chronic kidney disease, or diabetes. Flow cytometry was used to quantify pFCG at a core laboratory. High and low pFCG were defined by a prespecified threshold. The primary end point was the composite of MI, stroke, and death. RESULTS: Patients treated with medical therapy alone (n=151) had a greater occurrence of the primary end point (23.8%) than those treated with PCI (n=490, 8.8%). The pFCG test discriminated to a similar extent the risk of the primary end point in both the medical treatment group (hazard ratio, 2.29 [95% CI, 1.18–4.41]; P =0.014) and the PCI group (hazard ratio, 2.57 [95% CI, 1.41–4.69]; P =0.002). There was no significant association between pFCG and clinically relevant bleeding in the medical treatment group (hazard ratio, 1.22 [95% CI, 0.29–5.10]) or the PCI group (hazard ratio, 1.56 [95% CI, 0.67–3.61]). CONCLUSIONS: Quantifying pFCG discerned the risk of subsequent cardiovascular events among patients treated with medical therapy alone or PCI. This prognostic information will be useful for clinical decisions that balance ischemic and bleeding risk. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05175261.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PlateletsNon-ST Elevated Myocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsReceptors, IgGST Elevation Myocardial InfarctionAgedFemaleHumansMaleMiddle AgedBiomarkersPredictive Value of TestsProspective StudiesRisk AssessmentRisk FactorsStrokeTime FactorsTreatment Outcome

Stichwörter der Autor:innen

coronary artery diseaseflow cytometrymyocardial infarctionpercutaneous coronary interventionprognosis

Substanzen

BiomarkersPlatelet Aggregation InhibitorsReceptors, IgG

Autor:innen und Institutionen

  • Department of Medicine, Cardiovascular Research Institute, The University of Vermont, Burlington (D.J.S.).
  • Department of Medicine, Hartford Hospital, CT (S.R.M.M.).
  • Division of Cardiology, Department of Medicine, University of Florida, Jacksonville (D.J.A.).
  • Department of Medicine, University of Pennsylvania, Philadelphia (A.C.F.).
  • Adventist Healthcare White Oak, Silver Spring, MD (H.I.).
  • Division of Cardiovascular Medicine, Maine Medical Center, Portland, ME (P.K.H.).

ORCID-Profile: David J Schneider, Dominick J Angiolillo, Alexander C Fanaroff, Patrick K Hohl, Mark B Effron

Zitieren

APA

Schneider, D. J., McMahon, S. R., Angiolillo, D. J., Fanaroff, A. C., Ibrahim, H., Hohl, P. K., Wanamaker, B. L., Effron, M. B., DiBattiste, P. M., & Investigators (2025). Predictive Value of Platelet FcγRIIa in Patients Treated With PCI Compared With Medical Therapy Alone After Myocardial Infarction. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.124.014939

Vancouver

Schneider DJ, McMahon SR, Angiolillo DJ, Fanaroff AC, Ibrahim H, Hohl PK, et al. Predictive Value of Platelet FcγRIIa in Patients Treated With PCI Compared With Medical Therapy Alone After Myocardial Infarction. Circulation: Cardiovascular Interventions. 2025. doi:10.1161/circinterventions.124.014939

BibTeX
@article{Schneider2025,
  author = {Schneider, David J and McMahon, Sean R and Angiolillo, Dominick J and Fanaroff, Alexander C and Ibrahim, Homam and Hohl, Patrick K and Wanamaker, Brett L and Effron, Mark B and DiBattiste, Peter M and Investigators, Investigators},
  title = {Predictive Value of Platelet FcγRIIa in Patients Treated With PCI Compared With Medical Therapy Alone After Myocardial Infarction},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2025},
  doi = {10.1161/circinterventions.124.014939}
}
Kostenlos starten →